Difference between revisions of "Vincristine (Oncovin)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Thrombotic thrombocytopenic" to "[[Category:Acquired thrombotic thrombocytopenic") |
Warner-admin (talk | contribs) m (Text replacement - "'''contains dosing details in manuscript'''" to "'''dosing details in manuscript have been reviewed by our editors'''") |
||
| (12 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.<ref name="insert">[http://patient.cancerconsultants.com/druginserts/Vincristine.pdf Vincristine (Oncovin) package insert]</ref><ref>[ | + | Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.<ref name="insert">[http://patient.cancerconsultants.com/druginserts/Vincristine.pdf Vincristine (Oncovin) package insert]</ref><ref>[https://hemonc.org/docs/packageinsert/vincristine.pdf Vincristine (Oncovin) package insert (locally hosted backup)]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: [[vesicant]] | <br>Extravasation: [[vesicant]] | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is established ''(work in progress)''== | ==Diseases for which it is established ''(work in progress)''== | ||
| Line 27: | Line 27: | ||
*[[Hepatoblastoma]] | *[[Hepatoblastoma]] | ||
*[[HIV-associated lymphoma]] | *[[HIV-associated lymphoma]] | ||
| − | *[[Hodgkin lymphoma]] | + | *[[Classical Hodgkin lymphoma]] |
*[[Hodgkin lymphoma, nodular lymphocyte-predominant]] | *[[Hodgkin lymphoma, nodular lymphocyte-predominant]] | ||
*[[Kaposi sarcoma]] | *[[Kaposi sarcoma]] | ||
| Line 56: | Line 56: | ||
*[[Breast cancer_-_historical|Breast cancer]] | *[[Breast cancer_-_historical|Breast cancer]] | ||
*[[Chronic lymphocytic leukemia - historical|Chronic lymphocytic leukemia]] | *[[Chronic lymphocytic leukemia - historical|Chronic lymphocytic leukemia]] | ||
| + | *[[Chronic myeloid leukemia - historical|Chronic myeloid leukemia]] | ||
*[[Colon cancer - historical|Colon cancer]] | *[[Colon cancer - historical|Colon cancer]] | ||
*[[Head and neck cancer - historical|Head and neck cancer]] | *[[Head and neck cancer - historical|Head and neck cancer]] | ||
| Line 63: | Line 64: | ||
==Notable side effects== | ==Notable side effects== | ||
| − | *Neuropathy <ref>Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, van Duin M, el Jarari L, Bertsch U, Lokhorst HM, Durie BG, Goldschmidt H, Sonneveld P. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010 Nov;11(11):1057-65. Epub 2010 Sep 21. [https://doi.org/10.1016/S1470-2045%2810%2970206-0 link to original article] ''' | + | *Neuropathy <ref>Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, van Duin M, el Jarari L, Bertsch U, Lokhorst HM, Durie BG, Goldschmidt H, Sonneveld P. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010 Nov;11(11):1057-65. Epub 2010 Sep 21. [https://doi.org/10.1016/S1470-2045%2810%2970206-0 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/20864405/ PubMed]</ref> |
==Patient drug information== | ==Patient drug information== | ||
| Line 71: | Line 72: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
* 1963-07-10: Initial FDA approval | * 1963-07-10: Initial FDA approval | ||
| − | *2014-08-05 (oldest label available at Drugs @ FDA): Indicated in [[:Category:Acute leukemias|acute leukemia]]. It has also been shown to be useful in combination with other oncolytic agents in [[Hodgkin lymphoma|Hodgkin’s disease]], [[:Category:Non-Hodgkin lymphomas|non-Hodgkin’s malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular, and diffuse types)]], [[rhabdomyosarcoma]], [[neuroblastoma]], and [[Wilms tumor|Wilms’ tumor]]. ''(No supporting studies are cited)'' | + | *2014-08-05 (oldest label available at Drugs @ FDA): Indicated in [[:Category:Acute leukemias|acute leukemia]]. It has also been shown to be useful in combination with other oncolytic agents in [[Classical Hodgkin lymphoma|Hodgkin’s disease]], [[:Category:Non-Hodgkin lymphomas|non-Hodgkin’s malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular, and diffuse types)]], [[rhabdomyosarcoma]], [[neuroblastoma]], and [[Wilms tumor|Wilms’ tumor]]. ''(No supporting studies are cited)'' |
| − | + | ==History of changes in EMA indication== | |
| + | *1995-04-12: EURD | ||
| + | ==History of changes in PMDA indication== | ||
| + | *2013-03-25: New additional indication and a new dosage for the treatment of [[pheochromocytoma]]. | ||
==Also known as== | ==Also known as== | ||
*'''Generic names:''' LCR, leurocristine, VCR, vincristine sulfate | *'''Generic names:''' LCR, leurocristine, VCR, vincristine sulfate | ||
| Line 144: | Line 148: | ||
[[Category:Hepatoblastoma medications]] | [[Category:Hepatoblastoma medications]] | ||
[[Category:HIV-associated lymphoma medications]] | [[Category:HIV-associated lymphoma medications]] | ||
| − | [[Category:Hodgkin lymphoma medications]] | + | [[Category:Classical Hodgkin lymphoma medications]] |
[[Category:Hodgkin lymphoma, nodular lymphocyte-predominant medications]] | [[Category:Hodgkin lymphoma, nodular lymphocyte-predominant medications]] | ||
[[Category:Low-grade glioma medications]] | [[Category:Low-grade glioma medications]] | ||
| Line 173: | Line 177: | ||
[[Category:Breast cancer medications (historic)]] | [[Category:Breast cancer medications (historic)]] | ||
[[Category:Chronic lymphocytic leukemia medications (historic)]] | [[Category:Chronic lymphocytic leukemia medications (historic)]] | ||
| + | [[Category:Chronic myeloid leukemia medications (historic)]] | ||
[[Category:Colon cancer medications (historic)]] | [[Category:Colon cancer medications (historic)]] | ||
[[Category:Head and neck cancer medications (historic)]] | [[Category:Head and neck cancer medications (historic)]] | ||
| Line 180: | Line 185: | ||
[[Category:FDA approved in 1963]] | [[Category:FDA approved in 1963]] | ||
| + | [[Category:EMA approved in 1995]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Latest revision as of 20:33, 15 July 2024
General information
Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.[1]
Diseases for which it is established (work in progress)
- Non-Hodgkin lymphoma
Diseases for which it is used
- Adult T-cell leukemia-lymphoma
- Anaplastic glioma
- Anaplastic large cell lymphoma
- B-cell acute lymphoblastic leukemia
- Burkitt lymphoma
- CNS lymphoma
- Diffuse large B-cell lymphoma
- Ewing sarcoma
- Extranodal NK- and T-cell lymphoma, nasal type
- Gestational trophoblastic neoplasia
- Glioblastoma
- Hepatoblastoma
- HIV-associated lymphoma
- Classical Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Kaposi sarcoma
- Low-grade glioma
- Marginal zone lymphoma
- Mediastinal gray-zone lymphoma
- Medulloblastoma
- Multiple myeloma
- Neuroblastoma
- Penile cancer
- Pheochromocytoma
- Post-transplant lymphoproliferative disorder
- Primary mediastinal B-cell lymphoma
- Rhabdomyosarcoma
- Soft tissue sarcoma
- T-cell acute lymphoblastic leukemia
- Testicular cancer
- Acquired thrombotic thrombocytopenic purpura
- Thymoma
- Transformed lymphoma
- Waldenström macroglobulinemia
- Wilms tumor
Diseases for which it was used
- Acute myeloid leukemia
- Breast cancer
- Chronic lymphocytic leukemia
- Chronic myeloid leukemia
- Colon cancer
- Head and neck cancer
- Melanoma
- Osteosarcoma
- Small cell lung cancer
Notable side effects
- Neuropathy [3]
Patient drug information
- Vincristine (Oncovin) patient drug information (Chemocare)[4]
- Vincristine (Oncovin) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 1963-07-10: Initial FDA approval
- 2014-08-05 (oldest label available at Drugs @ FDA): Indicated in acute leukemia. It has also been shown to be useful in combination with other oncolytic agents in Hodgkin’s disease, non-Hodgkin’s malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular, and diffuse types), rhabdomyosarcoma, neuroblastoma, and Wilms’ tumor. (No supporting studies are cited)
History of changes in EMA indication
- 1995-04-12: EURD
History of changes in PMDA indication
- 2013-03-25: New additional indication and a new dosage for the treatment of pheochromocytoma.
Also known as
- Generic names: LCR, leurocristine, VCR, vincristine sulfate
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Alcrist | Biocrist | Biocrystin | Cellcristin | Citomid | Crivosin | Farmistin CS | Fauldvincri |
| Krebin | Kyocristine | Nevexitin | Oncovin | Onkocristin | Pericristine | Pharmacristine | Tecnocris |
| Vincasar | Vinces | Vincosid | Vincran | Vincrex | Vincrifil | Vincrin | Vincrisin |
| Vincrisol | Vincristin | Vincristina | Vincristinesulfaat | Vincristinsulfat | Vincristinum | Vincrisul | Vinracin |
| Vinracine | Vinstin | Vintec | |||||
References
- ↑ 1.0 1.1 Vincristine (Oncovin) package insert
- ↑ Vincristine (Oncovin) package insert (locally hosted backup)
- ↑ Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, van Duin M, el Jarari L, Bertsch U, Lokhorst HM, Durie BG, Goldschmidt H, Sonneveld P. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010 Nov;11(11):1057-65. Epub 2010 Sep 21. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- ↑ Vincristine (Oncovin) patient drug information (Chemocare)
- ↑ Vincristine (Oncovin) patient drug information (UpToDate)
Categories:
- Drugs
- Intravenous medications
- Vesicant
- Microtubule inhibitors
- Vinca alkaloids
- Adult T-cell leukemia-lymphoma medications
- Anaplastic glioma medications
- Anaplastic large cell lymphoma medications
- B-cell acute lymphoblastic leukemia medications
- Burkitt lymphoma medications
- CNS lymphoma medications
- Diffuse large B-cell lymphoma medications
- Ewing sarcoma medications
- Extranodal NK- and T-cell lymphoma, nasal type medications
- Follicular lymphoma medications
- Gestational trophoblastic neoplasia medications
- Glioblastoma medications
- Hepatoblastoma medications
- HIV-associated lymphoma medications
- Classical Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Low-grade glioma medications
- Low-grade glioma, pediatric medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Medulloblastoma medications
- Multiple myeloma medications
- Neuroblastoma medications
- Penile cancer medications
- Peripheral T-cell lymphoma medications
- Pheochromocytoma medications
- Post-transplant lymphoproliferative disorder medications
- Primary mediastinal B-cell lymphoma medications
- Rhabdomyosarcoma medications
- Soft tissue sarcoma medications
- T-cell acute lymphoblastic leukemia medications
- Testicular cancer medications
- Acquired thrombotic thrombocytopenic purpura medications
- Thymoma medications
- Transformed lymphoma medications
- Kaposi sarcoma medications
- Waldenström macroglobulinemia medications
- Wilms tumor medications
- Acute myeloid leukemia medications (historic)
- Breast cancer medications (historic)
- Chronic lymphocytic leukemia medications (historic)
- Chronic myeloid leukemia medications (historic)
- Colon cancer medications (historic)
- Head and neck cancer medications (historic)
- Melanoma medications (historic)
- Osteosarcoma medications (historic)
- Small cell lung cancer medications (historic)
- FDA approved in 1963
- EMA approved in 1995
- WHO Essential Cancer Medicine